Because most currently available integrin and selectin antagonists were selected for blocking integrin binding to known extracellular matrix ligands or CD62P binding to glycans, it would be prudent to develop inhibitors of CD62P–integrin site 2 interactions to determine their efficacy in inflammation and cancer. This evidence concerns the gene SELP and cancer.